Price T Rowe Associates Inc. MD Increases Stock Position in Vera Therapeutics, Inc. (NASDAQ:VERA)

Price T Rowe Associates Inc. MD grew its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 11.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 4,377,049 shares of the company's stock after buying an additional 437,940 shares during the quarter. Price T Rowe Associates Inc. MD owned 6.91% of Vera Therapeutics worth $185,107,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Huntington National Bank bought a new position in shares of Vera Therapeutics during the 4th quarter valued at approximately $26,000. AlphaQuest LLC bought a new stake in shares of Vera Therapeutics in the fourth quarter valued at $34,000. KBC Group NV lifted its position in shares of Vera Therapeutics by 127.2% during the 4th quarter. KBC Group NV now owns 2,477 shares of the company's stock valued at $105,000 after buying an additional 1,387 shares during the last quarter. Summit Investment Advisors Inc. grew its stake in shares of Vera Therapeutics by 16.0% during the 4th quarter. Summit Investment Advisors Inc. now owns 4,639 shares of the company's stock worth $196,000 after acquiring an additional 639 shares during the period. Finally, Moors & Cabot Inc. purchased a new stake in Vera Therapeutics in the 4th quarter worth about $220,000. Hedge funds and other institutional investors own 99.21% of the company's stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on the stock. Guggenheim lifted their target price on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research note on Thursday, February 27th. JPMorgan Chase & Co. lowered their target price on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating on the stock in a report on Tuesday, March 4th. Wolfe Research initiated coverage on Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price target for the company. Finally, The Goldman Sachs Group started coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 price target for the company. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Buy" and an average target price of $64.67.

Vera Therapeutics Price Performance

Shares of NASDAQ VERA traded up $1.00 during midday trading on Friday, hitting $24.75. 460,454 shares of the company's stock were exchanged, compared to its average volume of 749,056. The business's fifty day moving average price is $24.86 and its two-hundred day moving average price is $35.43. The company has a market cap of $1.58 billion, a price-to-earnings ratio of -9.49 and a beta of 1.28. The company has a current ratio of 13.76, a quick ratio of 13.76 and a debt-to-equity ratio of 0.17. Vera Therapeutics, Inc. has a 12-month low of $18.53 and a 12-month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. As a group, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.